Paclitaxel's mechanistic and clinical effects on breast cancer
Paclitaxel (PTX), the most widely used anticancer drug, is applied for the treatment of
various types of malignant diseases. Mechanisms of PTX action represent several ways in …
various types of malignant diseases. Mechanisms of PTX action represent several ways in …
Oncogenic Y‐box binding protein‐1 as an effective therapeutic target in drug‐resistant cancer
M Kuwano, T Shibata, K Watari, M Ono - Cancer science, 2019 - Wiley Online Library
Y‐box binding protein‐1 (YBX 1), a multifunctional oncoprotein containing an evolutionarily
conserved cold shock domain, dysregulates a wide range of genes involved in cell …
conserved cold shock domain, dysregulates a wide range of genes involved in cell …
Fasting-mimicking diet and hormone therapy induce breast cancer regression
I Caffa, V Spagnolo, C Vernieri, F Valdemarin… - Nature, 2020 - nature.com
Approximately 75% of all breast cancers express the oestrogen and/or progesterone
receptors. Endocrine therapy is usually effective in these hormone-receptor-positive …
receptors. Endocrine therapy is usually effective in these hormone-receptor-positive …
miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4
F Du, L Yu, Y Wu, S Wang, J Yao, X Zheng, S Xie… - Cell Death & …, 2019 - nature.com
Acquired resistance to chemotherapy is a major obstacle in breast cancer (BC) treatment.
Accumulated evidence has uncovered that microRNAs (miRNAs) are vital regulators of …
Accumulated evidence has uncovered that microRNAs (miRNAs) are vital regulators of …
Drug resistance in medulloblastoma is driven by YB-1, ABCB1 and a seven-gene drug signature
L Taylor, PK Wade, JEC Johnson, M Aldighieri… - Cancers, 2023 - mdpi.com
Simple Summary Medulloblastoma is the most common malignant childhood brain tumour.
Under standard therapy, relapse occurs in 30% of patients and is almost universally fatal …
Under standard therapy, relapse occurs in 30% of patients and is almost universally fatal …
Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer
M Gagliardi, MK Pitner, J Park, X Xie, H Saso… - Scientific reports, 2020 - nature.com
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer characterized
by metastasis, drug resistance and high rates of recurrence. With a lack or targeted …
by metastasis, drug resistance and high rates of recurrence. With a lack or targeted …
Silencing Y-box binding protein-1 inhibits triple-negative breast cancer cell invasiveness via regulation of MMP1 and beta-catenin expression
JP Lim, S Nair, S Shyamasundar, PJ Chua… - Cancer letters, 2019 - Elsevier
Abstract Y-box binding protein-1 (YB-1), an important transcription and translation regulator
protein, is known to increase cancer cell invasiveness and spreading. Here, we report its …
protein, is known to increase cancer cell invasiveness and spreading. Here, we report its …
ERK1/2-RSK2 signaling in regulation of erα-mediated responses
DA Lannigan - Endocrinology, 2022 - academic.oup.com
Signaling via extracellular regulated kinase 1/2 (ERK1/2) and p90 ribosomal S6 kinase
(RSK), a downstream effector, mediates numerous processes. For example, ERK1/2-RSK …
(RSK), a downstream effector, mediates numerous processes. For example, ERK1/2-RSK …
Egr-1 regulates irradiation-induced autophagy through Atg4B to promote radioresistance in hepatocellular carcinoma cells
WX Peng, YY Wan, AH Gong, L Ge, J Jin, M Xu, CY Wu - Oncogenesis, 2017 - nature.com
Although hepatocellular carcinoma (HCC) is usually response to radiation therapy,
radioresistance is still the major obstacle that limits the efficacy of radiotherapy for HCC …
radioresistance is still the major obstacle that limits the efficacy of radiotherapy for HCC …
Targeting phosphorylation of Y-box–binding protein YBX1 by TAS0612 and everolimus in overcoming antiestrogen resistance
T Shibata, K Watari, A Kawahara, T Sudo… - Molecular cancer …, 2020 - AACR
Nuclear expression of Y-box–binding protein (YBX1) is closely correlated with clinical poor
outcomes and drug resistance in breast cancer. Nuclear translocation of YBX1 is facilitated …
outcomes and drug resistance in breast cancer. Nuclear translocation of YBX1 is facilitated …